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Malaria and iron have a complex but important relationship. Plasmodium proliferation
requires iron, both during the clinically silent liver stage of growth and in the disease-
associated phase of erythrocyte infection. Precisely how the protozoan acquires its iron
from its mammalian host remains unclear, but iron chelators can inhibit pathogen growth
in vitro and in animal models. In humans, iron deﬁciency appears to protect against
severe malaria, while iron supplementation increases risks of infection and disease.
Malaria itself causes profound disturbances in physiological iron distribution and utilization,
through mechanisms that include hemolysis, release of heme, dyserythropoiesis, anemia,
deposition of iron in macrophages, and inhibition of dietary iron absorption. These
effects have signiﬁcant consequences. Malarial anemia is a major global health problem,
especially in children, that remains incompletely understood and is not straightforward
to treat. Furthermore, the changes in iron metabolism during a malaria infection may
modulate susceptibility to co-infections. The release of heme and accumulation of iron
in granulocytes may explain increased vulnerability to non-typhoidal Salmonella during
malaria. The redistribution of iron away from hepatocytes and into macrophages may
confer host resistance to superinfection, whereby blood-stage parasitemia prevents the
development of a second liver-stage Plasmodium infection in the same organism. Key to
understanding the pathophysiology of iron metabolism in malaria is the activity of the iron
regulatory hormone hepcidin. Hepcidin is upregulated during blood-stage parasitemia and
likely mediates much of the iron redistribution that accompanies disease. Understanding
the regulation and role of hepcidin may offer new opportunities to combat malaria and
formulate better approaches to treat anemia in the developing world.
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INTRODUCTION
Among themany nutrients required for human survival, iron plays
a unique role in determining disease susceptibility. This relation-
ship is especially well studied in the case of malaria. Parasites of the
genus Plasmodium cause malaria, although “malaria” is generally
used to refer to symptomatic Plasmodium falciparum infection,
unless otherwise speciﬁed. Malaria is currently one of the most
geographicallywidespread anddeadly diseases, and responsible for
the deaths of an estimated 600,000 people per year (MalariaWorld
Report, 20131). The controversial relationships between malaria
and ironhave been the subject of widespreaddiscussion anddebate
by the global health community since 2006, when a randomized
large-scale trial on the island of Pemba found that iron supplemen-
tation in children was linked with an increase in malaria-related
mortality (Sazawal et al., 2006). Two Cochrane reviews (Ojukwu
et al., 2009; Okebe et al., 2011) published subsequent to this ﬁnding
have not resolved this conundrum for physicians and policymak-
ers. Furthermore, while iron supplementation appears to be linked
with increased malarial mortality, malaria infections are a major
global cause of anemia (Kassebaum et al., 2014); and measures
taken todecreasemalaria at a population level also decrease anemia
(Meremikwu et al., 2012).
1http://www.who.int/malaria/publications/world_malaria_report_2013/en/
The interactions between malaria and iron have only lately
begun to be understood at the molecular level. Primarily, the
discovery of the iron regulatory hormone hepcidin has given us
new understanding of human iron physiology and pathophysiol-
ogy. Hepcidin serves to block iron absorption from the diet and
also to route iron in the body into macrophages and away from
the serum. Hepcidin plays a complex but vital role in both the iron
restriction that occurs during malaria infection, and in determin-
ing iron status and thereby inﬂuencing disease susceptibility. In
this review, we examine the known interactions between physio-
logical iron deﬁciency or repletion, iron supplementation,malaria,
and hepcidin, and offer recommendations and suggestions for
future work.
IRON DEFICIENCY PROTECTS FROM MALARIA INFECTION
Variations in the iron levels of susceptible hosts may modulate the
frequency and clinical severity of malaria infections. Gwamaka
et al. (2012) collected detailed data from a large cohort of Tan-
zanian children (birth – 3 years). In this vulnerable population,
iron deﬁciency at healthy aparasitemic visits was strongly associ-
ated with decreased future risk of parasitemia and severe malaria
(Gwamaka et al., 2012). Iron deﬁciency in this study was deﬁned
by low ferritin (<30 ng/mL) in individuals with low C-reactive
protein (CRP). A higher ferritin cutoff (<70 ng/mL) was used to
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deﬁne individuals with higher CRP as iron deﬁcient; plasma fer-
ritin is considered to be representative of iron stores in healthy
individuals but increases acutely in infections.
A further study in a slightly older cohort of Kenyan children
(8 months–8 years) found that iron repletion (deﬁned as fer-
ritin≥ 12 ng/mL,with transferrin saturation≥10%, children with
high CRP excluded), was predictive of clinical malaria episodes in
the year following measurement (Nyakeriga et al., 2004). Sepa-
rately, Jonker et al. (2012b) noted a similar effect in Malawian
children (6 months–5 years): iron-deﬁcient children (deﬁned as
plasma ferritin <30 ng/mL), had a lower incidence of clinical
malaria the subsequent year.
Studies performed in pregnant women also may indicate an
association between iron deﬁciency and protection from clinical
malaria, although somewhat less data are available. Two cross-
sectional studies have found that at the time of delivery, placental
malaria was associated with iron replete status (Kabyemela et al.,
2008; Senga et al., 2011). A limitation of this approach is that all
currently used measures of iron status, such as ferritin, can be
distorted by inﬂammation and infection, and thus cross-sectional
studiesmay be of limited utility in understanding this relationship.
Only one study has so far attempted to examine the predictive val-
ues of iron status on future placental or peripheral parasitemia in
pregnant women (Senga et al., 2012). This study measured iron
status by examining zinc protoporyphyrin (ZPP) levels. At both
the ﬁrst antenatal visit and at delivery, levels of ZPP indicative of
iron repletion were associated with parasitemia; however, analyz-
ing these data for ZPP as a predictivemeasure were complicated by
the elevation of ZPP by concurrent parasitemia. The authors con-
cluded that in this population,with a high incidence of parasitemia
and associated inﬂammation, ZPP alone is not a valid measure of
iron status, a concern that also could be applied to pediatric popu-
lations. Although the available data suggest a relationship, further
studies that recruit women early in pregnancy, stratify carefully
by gravidity and malaria transmission intensity, and follow their
outcomes closely are required to deﬁnitively answer the question
of whether iron status in women can predict malaria risk, as in
pediatric populations.
IRON SUPPLEMENTATION AND MALARIA INFECTION
While iron deﬁciency appears to offer some protection against
malaria, iron supplementation may increase the vulnerability of
susceptible populations to infection. Consequently, the use of
population-scale iron supplementation in malaria-endemic areas
is currently highly controversial. Early studies postulated a link
between oral intake of iron and malaria susceptibility (Murray
et al., 1978), as exempliﬁed by ﬂare-ups of latent infections fol-
lowing refeeding (Murray et al., 1975; Murray and Murray, 1977)
or differing malaria susceptibility associated with different diets
(Murray et al., 1980). In 2006, the “Pemba trial,” a large-scale,
randomized trial of iron supplementation in an area with very
high malaria transmission, was stopped prematurely when trial
monitoring boards found a link between the supplementation of
children with iron and folic acid and subsequent malaria infection
and mortality (Sazawal et al., 2006). Several studies that followed
the Pemba trial produced results that appeared to contradict this
ﬁnding, showing either no association between supplementation
and malaria risk (Desai et al., 2003; Ouedraogo et al., 2008), or a
protective effect of iron supplementation (Zlotkin et al., 2013).
However, many of the studies that followed the Pemba trial
were smaller in scale and/or introduced measures to combat
malaria, such as bednets or intermittent preventative chemo-
prophylaxis, which may have masked any increase in malaria
susceptibility.
TwoCochrane reviews have since been published in attempts to
reconcile the apparently disparate ﬁndings of the Pemba study and
subsequent trials (Ojukwu et al., 2009; Okebe et al., 2011). Both
reviews concluded that iron supplementation did not increase the
risk of malaria infection in children when“regularmalaria surveil-
lance and treatment services”were provided. However,many areas
of the world have inadequate malaria surveillance and treatment,
coupled with high levels of iron deﬁciency and anemia. We would
posit that two major questions remain unanswered by the current
literature.
First, to what degree must malaria be controlled, or treat-
ment and prevention practices put in place, before the beneﬁts
of giving iron outweigh the risks? This question remains prac-
tically difﬁcult to answer due to the ethical difﬁculties inherent
in providing iron supplementation without introducing malaria-
reductionmeasures, but further guidance is required for clinicians,
nutritionists, and policymakers.
A second and related question is: should iron supplementa-
tion be restricted to those children who are anemic and/or iron
deprived? The updated Cochrane review found that the beneﬁts
of iron supplementation were greatest among children who had
the lowest hemoglobin levels at baseline (Okebe et al., 2011). Not
only might these children reap the greatest beneﬁts from sup-
plementation, they may also be less likely to exhibit increased
malaria incidence or severity as a consequence of increased iron
stores. In a substudy of the Pemba trial, in which children were
more closely monitored and given malaria-reduction measures
such as insecticide-treated bednets (ITNs), the authors did not
ﬁnd that iron supplementation associated with increased malaria
incidence or mortality (Sazawal et al., 2006). Moreover, children
in this substudy who were iron deﬁcient and anemic at base-
line showed a signiﬁcant reduction in adverse events, including
malaria episodes, when supplemented with iron and folic acid
(Sazawal et al., 2006). This ﬁnding was apparently echoed by a
subsequent study that examined the effect of food fortiﬁcation
(micronutrient powders with or without iron) on malaria risk
in Ghanaian children (Zlotkin et al., 2013), which found that
children who were both iron deﬁcient and anemic at baseline
showed reduced incidence of malaria following iron supple-
mentation. However, as was mentioned in an editorial on this
study (Prentice et al., 2013) in the Ghanian trial, the iron-
containing micronutrient powders were not actually effective at
reducing anemia, making these results challenging to interpret.
Moreover, iron supplementation in this trial was found to be asso-
ciated with increased hospital admissions during the intervention
period.
Targeting iron supplementation toward iron-deﬁcient or ane-
mic children is complicated by both practical and ﬁscal obsta-
cles. As previously stated, most indicators of iron status can
be confounded by infection or inﬂammation, limiting their
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interpretation in the ﬁeld, and the widespread use of such tests
may be difﬁcult to fund. A solution to the problem may be
to ﬁnd more efﬁcient ways to avoid giving iron to individu-
als who are iron replete, infected, or at high risk of infection
(Atkinson et al., 2014). For example, in many areas, malaria
transmission and prevalence of iron deﬁciency is seasonal; iron
supplementation given outside of the malaria season may be less
likely to increase susceptibility to infection, although studies are
required to assess whether sub-patent parasitemias during the
dry season may be increased by iron supplementation and cause
illness.
When considering supplementation guidelines in pregnant
women, it should be considered that primigravidae are both more
susceptible to malaria infection and less prone to iron deﬁciency.
One study demonstrated that intravenous iron supplementation
increased malaria frequency in primigravidae but not multigravi-
dae (Oppenheimer et al., 1986). Studies focusing on the effects of
randomized oral iron supplementation have produced differing
results (Menendez et al., 1994; Nacher et al., 2003), but relatively
few have been performed thus far. In a large cohort study, it
was found that iron-replete primigravidae are signiﬁcantly more
likely to experience placental malaria, but this effect loses signif-
icance in multigravidae (Kabyemela et al., 2008; Friedman et al.,
2009). Summarizing the available evidence, adjusted supplemen-
tation guidelines that recommend lower iron supplementation to
primigravidae may be advantageous.
HOW THE MALARIA PARASITE BENEFITS FROM IRON
Iron is a limiting factor for the growth of many bacterial or pro-
tozoan pathogens. Iron-chelating agents such as desferrioxamine
have been shown to restrict malaria growth in vitro (Raventos-
Suarez et al., 1982), inmurinemodels of malaria infection (Fritsch
et al., 1985; Ferrer et al., 2012), and in malaria-infected monkeys
(Pollack et al., 1987) (reviewed in Mabeza et al., 1999). Conse-
quently, iron-chelating agents have been considered as an adjunct
or primary antimalarial therapy.
In humans, preliminary work on the use of the iron chela-
tors desferrioxamine, or the orally administered deferiprone, as
an adjunct to standard antimalarial therapy seemed promising
(Traore et al., 1991). However, after further studies showed no
clear beneﬁt from administration of chelators, and one seemed to
hint at a slight increase in mortality in the trial group treated with
desferrioxamine (Thuma et al., 1998), a Cochrane review recom-
mended that trials testing iron chelators for malaria treatment be
discontinued (Smith and Meremikwu, 2003).
The development of antimalarial drugs that target the para-
site’s access to iron might meet with more success if we had a
better understanding of how Plasmodium parasites acquire iron
during their various life stages. Blood-stage parasites have been
theorized to acquire iron from serum transferrin (Rodriguez and
Jungery, 1986), from iron produced during the breakdown of
hemoglobin, or from a free pool of intracellular iron (Hershko
and Peto, 1988), but this important issue remains unresolved.
Very little work has been done that investigates the acquisi-
tion of iron by the obligate liver or mosquito life stages of
malaria infection; these continue to be fruitful areas for future
research. For example, identiﬁcation of Plasmodium-encoded
iron transporters would both increase our understanding of
the mechanism by which different life stages obtain their iron,
and provide new drug targets aimed at inhibiting parasite
growth.
Iron repletionmay also have effects on parasite growth through
different mechanisms than direct utilization by the parasite. A
full synopsis of the literature is beyond the scope of this review,
but iron has many effects on the immune system (McDer-
mid and Prentice, 2006). In malaria speciﬁcally, it has been
suggested that parasitized red blood cells from iron-deﬁcient
hosts may be more efﬁciently phagocytized, based on evidence
from a murine model (Matsuzaki-Moriya et al., 2011). Finally,
some Plasmodium species, notably P. vivax, live preferentially in
young reticulocytes. Reticulocyte production can be restricted in
highly anemic hosts, and this has been proposed as a mechanis-
tic explanation for a study that showed an inverse association
between severe anemia and P. vivax infection (Manning et al.,
2012).
HUMAN IRON CONTROL: THE HORMONE HEPCIDIN
Systemic mammalian iron metabolism is controlled at the level
of iron absorbance from the diet and iron recycling through
macrophages. Approximately 1 mg of iron is absorbed from the
diet every day, roughly equivalent to the iron that is lost daily in
poorly regulated activities such as sweating, any bleeding, and the
sloughing off of enterocytes. At the same time, iron already in
the body is constantly being recycled as macrophages phagocy-
tose senescent or damaged red blood cells, digest the heme and
extract the iron they contain, and export that iron back into the
circulation.
The export of iron across the basolateral membrane of entero-
cytes and the recyclingof iron throughmacrophages are dependent
on the same transport protein: ferroportin, the sole currently iden-
tiﬁed mammalian iron export protein (Abboud and Haile, 2000;
Donovan et al., 2000; McKie et al., 2000). The release of iron from
enterocytes into the bloodstream is the ﬁnal step of absorption
of iron from the diet. Hepcidin, discovered a decade ago by three
groups working independently (Krause et al., 2000; Pigeon et al.,
2001; Park et al., 2001), is a 25-amino acid protein that binds to fer-
roportin and causes it to be internalized and degraded (Nemeth
et al., 2004). The effect of ferroportin inhibition by hepcidin is
therefore to block uptake of dietary iron from the intestine, and
to increase the accumulation of iron in macrophages. The result
is a decrease in serum iron levels, which routes iron away from
pathogens that could potentially exploit circulating iron, but may
also render the host anemic by restricting iron availability to the
erythron.
Evidence from both animal models and from human genetic
lesions suggests that the hepcidin–ferroportin interaction is
functionally non-redundant. Mice underexpressing hepcidin are
severely iron-overloaded (Nicolas et al., 2001), mimicking the
human genetic disorder hereditary hemochromatosis, which (in
rare cases) is caused by genetic lesions in the hepcidin gene itself
(Roetto et al., 2003), in genes that encode hepcidin-regulatory
factors (Bridle et al., 2003), or by mutations in ferroportin that
render it resistant to hepcidin control (Drakesmith et al., 2005).
Conversely, mice that overexpress hepcidin are fatally anemic
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(Nicolas et al., 2002a), while patients with mutations that lead
to chronic hepcidin overexpression suffer from iron-refractory
iron-deﬁciency anemia (Finberg et al., 2008).
Hepcidin increases in response to high iron conditions (Pigeon
et al., 2001), but it is also upregulated in response to infectious
and inﬂammatory stimuli (Nicolas et al., 2002b). Hepcidin is con-
trolled homeostatically primarily via the bone morphogenetic
protein (BMP) pathway. BMPs signal through the phosphoryla-
tion of SMAD transcription factors, which bind to a well-studied
site on the hepcidin promoter and increase hepcidin transcription
(Wang et al., 2005). Inﬂammation and infection also induce inter-
leukin (IL)-6 or IL-22, which can upregulate hepcidin through the
phosphorylation of STAT3 (Nemeth et al., 2003; Armitage et al.,
2011). BMP/SMAD signaling has also recently been linked to
hepcidin upregulation in infectious or inﬂammatory conditions
by the molecule activin B, another member of the transform-
ing growth factor β (TGFβ) superfamily that is upregulated by
inﬂammatory stimuli but acts to upregulate hepcidin through
SMAD signaling (Besson-Fournier et al., 2012). Hepcidin is sup-
pressed by anemia, hypoxia, or erythropoietic drive, but, at
the time of writing, the pathways underlying hepcidin sup-
pression are less well articulated than are those involved in its
upregulation.
UPREGULATION OF HEPCIDIN IN MALARIA: CAUSES AND
CONSEQUENCES
Hepcidin is upregulated in infections by bacterial, fungal, and viral
pathogens (Armitage et al., 2011). Multiple studies have found
that hepcidin is upregulated in malaria infection in symptomatic
and asymptomatic natural human infections (Howard et al., 2007;
de Mast et al., 2009a, 2010), in experimentally controlled human
infections (deMast et al., 2009b), and inmurinemodels of malaria
infection (Portugal et al., 2011; Wang et al., 2011). Resolution of
infection leads to normalization of hepcidin levels (de Mast et al.,
2009a).
Hepcidin’s upregulation in malaria has several important con-
sequences. First, the upregulation of hepcidin leads to iron
accumulation in macrophages and a decrease in serum iron,
possibly contributing to the dyserythropoiesis and anemia that
can accompany malaria infections. Additionally, hepcidin upreg-
ulation directly blocks dietary iron absorption: children with
post-malarial anemia have high hepcidin levels and poorly incor-
porate orally administered iron into their red blood cells (Prentice
et al., 2012).
The mechanisms whereby hepcidin is upregulated in malaria
infection have yet to be fully characterized. IL-6 has been
shown to be correlated with hepcidin in some studies (Casals-
Pascual et al., 2012; Burte et al., 2013; Jonker et al., 2013), but
in another study, urinary IL-6 and hepcidin were not signiﬁ-
cantly associated after a multiple, stepwise linear regression in
infected humans (de Mast et al., 2009a). In one ex vivo study,
human peripheral blood mononuclear cells co-incubated with
Plasmodium-infected red blood cells showed a signiﬁcant upreg-
ulation of hepcidin mRNA without concomitant IL-6 message
increase (Armitage et al., 2009), but the relative contribution of
peripheral blood mononuclear cells to systemic hepcidin lev-
els is unknown. Finally, a study looking at the mechanisms by
which blood-stage malaria infection can prevent the establish-
ment of a liver-stage infection, which is thought to be modulated
by hepcidin, found that liver-stage inhibition was preserved in
mice treated with anti-IL-6 antibodies (Portugal et al., 2011).
In brief, the role of IL-6 in hepcidin regulation in malaria
remains controversial, and it is, as yet, unclear which other
pathways may contribute to hepcidin upregulation in malaria
infection.
Despite the paucity of knowledge on precisely how hepcidin
is upregulated in malaria, the fact that both infection and iron
repletion lead to increased hepcidin, and that increased hep-
cidin prevents oral iron absorption, suggests its potential utility
as a point of care test to guide iron supplementation in areas of
high infectious burden. Low hepcidin would indicate both the
absence of infection and the probability of efﬁcient iron absorp-
tion, while high hepcidin would indicate either adequate iron
stores or ongoing infection. In the latter situation, iron sup-
plementation would likely be unnecessary due to adequate iron
stores, poorly absorbed as a direct result of high hepcidin, and/or
potentially harmful if hepcidin is elevated due to an ongoing
infection.
UPREGULATION OF HEPCIDIN IN MALARIA: FOCUSING ON
CO-INFECTION
Hepcidin has been recently shown to play a crucial role in deter-
mining the multiplicity of malaria infections within a single host.
The obligate liver stage of the malaria parasite requires iron: hep-
cidin peptide injection or hepcidin overexpression by transgene or
viral vector can reduce parasite survival at the crucial hepatic bot-
tleneck (Portugal et al., 2011). The hepcidin upregulation initiated
by one blood-stage infection thereby blocks the establishment of
a second infection (Portugal et al., 2011).
The physiological redistribution of iron as a consequence
of hepcidin upregulation may also have a signiﬁcant effect on
host susceptibility to other bacterial, viral, or protozoa parasites
(see Figure 1). In a blood-stage malaria infection, raised hep-
cidin is expected to contribute to increased macrophage iron
levels, as does increased erythrophagocytosis. This increase in
bioavailable macrophage iron may beneﬁt pathogens that exploit
the macrophage niche (van Santen et al., 2013). In particu-
lar, hepcidin upregulation may help to explain the association
between malaria infections and susceptibility to non-typhoid
salmonella (NTS). The epidemiological link between malaria
and NTS is well established (Mabey et al., 1987). Iron has been
implicated in the contribution of malaria to NTS susceptibil-
ity through increases in both free heme and heme-oxygenase
expression (Cunnington et al., 2012). By routing iron to accu-
mulate in macrophages, the hepcidin response to malaria may
also render the host more vulnerable to NTS directly (van
Santen et al., 2013). Similarly, tuberculosis could conceivably
beneﬁt from the increased iron availability in its macrophage
niche, but the speciﬁc role of iron and hepcidin in this impor-
tant co-infection has not been examined at the time of writ-
ing.
An important question is whether malaria-induced alteration
of iron metabolism may modulate susceptibility to viral infec-
tions and vice versa. Malaria infections are associated with
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FIGURE 1 | Hypotheses for the effect of co-infections on iron
metabolism. (A) Possible implications of blood-stage malaria infection on
host susceptibility to other infections. Blood-stage parasitemia causes
hepcidin upregulation, which in turn routes iron away from hepatocytes and
lowers serum iron levels, blocking the erythron’s access to iron and causing
anemia. Lowered hepatocyte iron levels prevent the establishment of a
second malaria infection (superinfection) by blocking liver-stage growth.
Hepcidin also causes iron levels to increase in macrophages and potentially in
enterocytes as well, thus possibly giving an advantage to pathogens that
exploit the macrophage niche (non-typhoidal salmonella, tuberculosis,
Toxoplasma) and those that require iron in enterocytes (Toxoplasma).
(B) Hypothesized effect of HCV infection on malaria susceptibility. Long-term
HCV infection causes hepcidin suppression, thus increasing liver iron stores
and plausibly increasing malaria susceptibility. (C) Potential impact of
intestinal helminth infection. Helminths cause periodic blood loss, which
restricts iron to the liver, potentially blocking malaria liver-stage infection as in
(A). Decreases in serum restrict iron availability for erythropoiesis, causing
anemia, which in turn causes the downregulation of hepcidin.
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higher HIV viral load (Kublin et al., 2005). In turn, HIV-infected
individuals are at greater risk of malarial infection (Patnaik
et al., 2005). HIV affects iron metabolism in a complex man-
ner: HIV is commonly associated with anemia, and in one
study, hepcidin levels were shown to be elevated in HIV infec-
tion and inversely correlated with CD4 counts (Wisaksana et al.,
2013). Conversely, increased iron stores in HIV-infected individu-
als are associated with mortality (McDermid et al., 2007, 2009)
and risk of tuberculosis infection (McDermid et al., 2013). In
an HIV-infected host, how do perturbations in iron and hep-
cidin modulate host susceptibility to malaria? Interestingly, HIV
antiviral drugs have been found to demonstrate anti-Plasmodium
activity at asexual (Skinner-Adams et al., 2004), liver (Hobbs et al.,
2009), and gametocyte (Hobbs et al., 2013) life stages. However
the effect of combination therapy on Plasmodium in HIV-1-
positive patients, and the interactions of anti-retrovirals with anti-
malarials and their overall effect on ironmetabolism are difﬁcult to
predict.
Chronic hepatitis C virus (HCV) infection leads to hepcidin
suppression and concomitant hepatic iron overload (Girelli et al.,
2009). Might this increased iron lead to increased malaria sus-
ceptibility? Exposure of mice to HCV RNA induces a type 1
interferon response that has the effect of reducing parasite liver
infection 48 h later (Liehl et al., 2014), but a long-term pro-
ductive HCV infection and consequent iron overload may affect
malaria risk very differently. More studies are needed to establish
how chronic viral infections alter iron metabolism and malaria
susceptibility.
Another unresolved issue is the effects of malaria on toxoplas-
mosis susceptibility. Toxoplasma gondii is carried asymptomat-
ically by a large proportion of the human population, and it
can cause life-threatening infections in pregnant women and the
immunosuppressed. Toxoplasma infects hosts via enterocytes and
can live in hostmacrophages (Hunter and Sibley, 2012). One study
has shown that interferon gamma causes the death of Toxoplasma
in enterocytes in a manner dependent on the depletion of intra-
cellular iron stores (Dimier and Bout, 1998). Upregulation of
hepcidin by a malaria infection would likely route iron toward
enterocytes and macrophages, thus plausibly increasing host sus-
ceptibility and/or tolerance of Toxoplasma. If Toxoplasma does
require intracellular iron stores to withstand the host response,
then hepcidin upregulation and subsequent routing of iron to
macrophages and enterocytes might increase host susceptibility to
Toxoplasma infection.
A major cause of iron deﬁciency and anemia in the developing
world is intestinal helminth infection. Infection with helminths
is strongly associated with anemia in children (Calis et al., 2008;
Jonker et al., 2012a); and de-worming treatment at the popula-
tion level decreases anemia levels (reviewed in Smith and Brooker,
2010). Complex data exist on the contributions of intestinal
helminth infections tomalaria susceptibility and severity (Salgame
et al., 2013). Early studies claimed that high-population helminth
infection was associated with a striking lack of malaria, which
the authors suggested was due to the nutritional perturbations
associated with the worms (Murray et al., 1977). This ﬁnding was
corroborated by more recent evidence suggesting that helminth
infection in young childrenmay be associated with fewer and later
malaria episodes (Lyke et al., 2005), or protection from some of
the potentially severemanifestations of malaria infections (Nacher
et al., 2001, 2002). These effects remain controversial; further work
has shown associations between helminths and higher parasitemia
(Degarege et al., 2012) or severe malaria (Le Hesran et al., 2004). A
single study found that infection with ﬁlarial worms ameliorated
the drop in hemoglobin and reduced inﬂammatory cytokine pro-
duction during malaria infection (Dolo et al., 2012). The impact
of helminth infections on hepcidin is not well established, but it is
plausible that helminth infection may, through periodic intesti-
nal bleeding, cause constitutionally low hepcidin, as the body
attempts to recoup the lost iron. At the same time, by causing
iron deﬁciency, helminth infection may decrease host susceptibil-
ity to malaria or accentuate the effects of a hepcidin increase in
infection.
Most laboratory studies on iron/infection interactions to date
have focused on the effect of a single pathogen. Throughout
human history, however, as well as in developing nations where
infectious disease is still highly prevalent, susceptible individ-
uals are frequently prey to multiple pathogens simultaneously.
Understanding how pathogens affect ironmetabolism and thereby
modulate host susceptibility to other infections is likely to prove
important both for its implications on treatment and on public
health recommendations.
SUPPRESSION OF HEPCIDIN IN SEVERE MALARIA
SYNDROMES
Although the majority of studies on hepcidin and malaria have
demonstrated an upregulation of hepcidin in malaria infection,
three recent studies have shown that in certain circumstances,
hepcidin suppressionmay also occur. One study found that among
all children presenting with malaria, those with severe anemia
had the lowest hepcidin levels (Casals-Pascual et al., 2012). A fur-
ther study (Burte et al., 2013) demonstrated that children with
uncomplicated malaria had higher hepcidin levels than those
who could be classiﬁed as either presenting with severe anemia
(in all studies cited, severe anemia was deﬁned as Hb ≤5 g/L)
or cerebral malaria. Finally, a group of children with severe
malarial anemia exhibited very low hepcidin serum levels (over
50% were undetectable by the study’s method; Jonker et al.,
2013).
Taken together, these studies clearly indicate that in severe
malarial anemia, the signaling pathway that suppresses hepcidin
can override the activation pathways associated with parasitemia.
The mechanisms of hepcidin suppression by erythropoietic drive,
hypoxia, or iron deﬁciency have not yet been well deﬁned, but
some groups have posited the existence of a bonemarrow-secreted
factor that suppresses hepcidin during erythropoiesis (Ginzburg
and Rivella, 2011). In the two human studies that compared
erythropoietin levels with serum hepcidin in malaria infection,
erythropoietin and hepcidin were negatively associated (Casals-
Pascual et al., 2012; Jonker et al., 2013). One animal study has also
demonstrated a signiﬁcant negative correlation between serum
erythropoietin and hepcidin liver message in mice infected with P.
berghei (Wang et al., 2011).
Further studies utilizing animal models of severe malarial ane-
mia will likely be required to explore this aspect of iron control
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in malaria infection. In addition, the role of iron and hepcidin in
cerebral malaria requires investigation.
MALARIA PREVENTION EFFORTS REDUCE ANEMIA
PREVALENCE
A recently published meta-analysis of global anemia prevalence
estimated that in 2010, the prevalence of anemia was 32.9%,
accounting for 8.8% of total years of life lived with disability
worldwide (Kassebaum et al., 2014). In malaria-endemic coun-
tries, malaria is a major contributor to anemia at the population
level: the authors estimated that in sub-Saharan African, 24.7% of
anemia is attributable to malaria (Kassebaum et al., 2014). There-
fore, interventions that reduce the prevalence of malaria could be
expected to result in a reduction in the severity and prevalence of
anemia.
The global community is currently usingmultiple complemen-
tary tools to reduce malaria at the population level. Intermittent
preventative treatment (IPT) refers to the practice of admin-
istering antimalarial drugs presumptively during the especially
vulnerable periods of pregnancy or early childhood. Insecticide-
treated bed nets (ITNs) reduce nocturnal bites from Anopheles
mosquitoes (Hill et al., 2006). Both interventions serve to pro-
tect the recipient and to reduce transmission at a population level
(Greenwood, 2004).
A recent Cochrane review examining the effects of IPT for chil-
dren under 5 concluded that of ﬁve West African trials examined,
there was likely a signiﬁcant reduction overall in moderate anemia
incidence in areas with seasonal P. falciparum malaria transmis-
sion (Meremikwu et al., 2012). Of the two trials, which considered
severe anemia as a separate outcome, both also found a signiﬁcant
reduction as a result of IPT (Dicko et al., 2011; Konate et al., 2011).
This is consistent with the ﬁndings of a previous Cochrane review,
which had also concluded that IPT in pregnant women was simi-
larly associated with decreased rates of both severe anemia and all
anemia (Garner and Gulmezoglu, 2006).
Fewer studies have examined the effects of the introduction of
ITNs only on anemia prevalence, but earlier introduction of ITNs
is associated with a statistically signiﬁcant reduction in anemia
prevalence in children at 6–12 months of age (Muller et al., 2006).
In another study, hemoglobin levels were found to be signiﬁcantly
associated with the use of ITNs in young children (Holtz et al.,
2002).
Why does reducing malaria infection have such a profound
effect on population anemia levels? The relationship between
malaria control and anemia risk may be partially dependent on
hepcidin and its effects on iron absorption and utilization (as well
as by reducing the well-known inhibitory effects of malaria on
erythropoiesis). The hepcidin increases associated with malaria
infection prevent efﬁcient iron uptake. Iron supplementation
has been shown to be less effective in areas with high malaria
transmission (Gera et al., 2007).
Two studies have delineated the effects of malaria infection
and hepcidin increase on the incorporation of orally adminis-
tered iron into erythrocytes (Doherty et al., 2008; Cercamondi
et al., 2010). In a study of young Beninese women, asymptomatic
parasitemia was associated with poor incorporation of orally
administered iron into RBCs, an effect that did not extend to
parentally administered iron. Treatment and resolution of para-
sitemia resulted in a decrease in serum hepcidin and improved
absorption of oral iron supplements (Cercamondi et al., 2010).
Similarly, young children with post-malarial anemia were
shown to poorly absorb orally administered iron supplements
(Doherty et al., 2008). Hepcidin levels in sera of these children
were measured subsequently; these hepcidin levels were shown to
be the best predictors of iron absorption (Prentice et al., 2012).
Furthermore, despite poor oral absorption of iron, these children
showed a more rapid hematological recovery than anemic and
aparasitemic children, suggesting that hepcidin upregulation in
malaria may contribute to relocalization of iron to macrophages,
rather than true iron deﬁciency.
Populations with a high prevalence of malaria infections may
therefore suffer both from anemia as a direct consequence of
malaria infections, but also from poor utilization of oral iron as a
result of chronically upregulated hepcidin.
DISCUSSION AND RECOMMENDATIONS
Anemia continues to be one of the most common causes of dis-
ability worldwide; while Plasmodium is one of the most prevalent
human pathogens. The relationship between the two is com-
plex: low iron status may protect against malaria infection, but
malaria infection in turn is linked with anemia at both the
individual and population levels. New clues to this relationship
have been obtained through our improved understanding of iron
metabolism.
Speciﬁcally, the relatively recent identiﬁcation of the human
iron hormone hepcidin has allowed us to begin to explore these
relationships in more depth. Hepcidin is upregulated in malaria
infection, likely contributing to anemia through the relocaliza-
tion of iron to macrophages and the prevention of iron uptake
from the diet. However, in certain severe malaria syndromes,
hepcidin may be suppressed. The mechanisms behind both hep-
cidin’s increase and its suppression in malaria are currently
unclear.
At the moment, action on three fronts is required. First,
we must implement our improved understanding of the iron–
malaria relationship toward optimizing malaria prevention and
anemia treatment. Research ﬁndings support more nuanced iron
supplementation regimens, rather than the blanket approach of
supplementing, or not supplementing, whole populations. Sup-
plementation could be scheduled around the malaria season
(Atkinson et al., 2014), routed to the most iron-deprived children
or pregnant women, or targeted based on hepcidin levels as a
proposed biomarker (Pasricha et al., 2014). At the very least, the
ﬁndings of the last decade of research since the Pemba trial argues
very strongly that iron supplementation should be carried out in
concert with malaria control efforts; and that improved malaria
control may itself be effective as a means of decreasing anemia at
the population level.
Second, clinically focused research is required to develop bet-
ter and rationally informed therapeutics for those who become
infected. For example, understanding the mechanisms underlying
hepcidin upregulation in malaria could be the ﬁrst step toward
the development of drugs that, given concurrently with anti-
malarial treatment, repress hepcidin and speed recovery from
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anemia. Carefully designed in vivo and in vitro studies could
explore the role that hepcidin may play in mediating the out-
comes of co-infections between malaria and other protozoan,
bacterial, or viral pathogens, providing vital information for treat-
ing individuals and populations exposed to multiple pathogens
simultaneously.
Finally, in the longer term, basic research should focus on an
improved understanding of the host–pathogen tug-of-war over
iron metabolism. How does malaria acquire iron at a molec-
ular level in its many life stages? Do malaria pathogens show
different phenotypes in iron-deprived hosts? Armed with new
tools to explore pathogen biology and iron metabolism, we have
a chance to answer questions of immediate clinical importance,
and to advance the basic science behind our understanding of the
host–parasite relationship.
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